Chromosome arm 3p has been widely recognized to harbor one or more tumor suppressor genes important in the development or progression of lung cancer. The minimally deleted region is quite extensive however, including over 60% of the short arm from 3p14 to p23 in SCLC. In non-SCLC, the minimally deleted region is smaller but less well defined; it appears to center around the 3p14 locus D3S3. Recent identification of an SCLC cell line with a submicroscopic deletion, the U2020 cell line, affords an opportunity to intensively investigate one small region of 3p for the presence of lung cancer associated tumor suppressor genes. the U2020 deletion is estimated to remove 4 to 5 megabases of 3p including the 3p14 locus D3S3. We have identified 7 additional markers deleted in U2020 and physically linked most of them over a region of 3.5 megabases. We have isolated yeast artificial chromosome (YAC) clones for all these markers and assembled many into contiguous cloned segments. the 33 YACs isolated so far contain about 4 megabases of the U2020 deletion. This proposal will use these YAC resources to develop a series of highly polymorphic markers along the U2020 deletion, and other selected regions of 3p. These polymorphic markers will then be used to survey lung tumors for loss of heterozygosity or small, homozygous or overlapping deletions. Tumors available for this analysis include up to 500 matched tumor-normal samples comprising non-SCLC cases and up to 200 unmatched SCLC cell lines. the primary aim of this proposal is to significantly narrow the target region within U2020 to uncover the location of one putative lung cancer tumor suppressor gene. this project will lay the foundation for future isolation and intensive study of this critically important tumor suppressor.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
1P50CA058187-01
Application #
3796262
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
1992
Total Cost
Indirect Cost
Name
University of Colorado Denver
Department
Type
DUNS #
065391526
City
Aurora
State
CO
Country
United States
Zip Code
80045
He, Yayi; Liu, Sangtian; Mattei, Jane et al. (2018) The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC. Drug Des Devel Ther 12:981-986
Genova, Carlo; Socinski, Mark A; Hozak, Rebecca R et al. (2018) EGFR Gene Copy Number by FISH May Predict Outcome of Necitumumab in Squamous Lung Carcinomas: Analysis from the SQUIRE Study. J Thorac Oncol 13:228-236
Merrick, Daniel T; Edwards, Michael G; Franklin, Wilbur A et al. (2018) Altered Cell-Cycle Control, Inflammation, and Adhesion in High-Risk Persistent Bronchial Dysplasia. Cancer Res 78:4971-4983
Li, Howard Y; McSharry, Maria; Walker, Deandra et al. (2018) Targeted overexpression of prostacyclin synthase inhibits lung tumor progression by recruiting CD4+ T lymphocytes in tumors that express MHC class II. Oncoimmunology 7:e1423182
Ravichandran, Kameswaran; Holditch, Sara; Brown, Carolyn N et al. (2018) IL-33 deficiency slows cancer growth but does not protect against cisplatin-induced AKI in mice with cancer. Am J Physiol Renal Physiol 314:F356-F366
Hilberg, Frank; Tontsch-Grunt, Ulrike; Baum, Anke et al. (2018) Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases. J Pharmacol Exp Ther 364:494-503
Noonan, Sinead A; Patil, Tejas; Gao, Dexiang et al. (2018) Baseline and On-Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene-Addicted Adenocarcinoma of the Lung. J Thorac Oncol 13:134-138
DeHart, David N; Fang, Diana; Heslop, Kareem et al. (2018) Opening of voltage dependent anion channels promotes reactive oxygen species generation, mitochondrial dysfunction and cell death in cancer cells. Biochem Pharmacol 148:155-162
Patil, Tejas; Smith, Derek E; Bunn, Paul A et al. (2018) The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib. J Thorac Oncol 13:1717-1726
Suda, Kenichi; Kim, Jihye; Murakami, Isao et al. (2018) Innate Genetic Evolution of Lung Cancers and Spatial Heterogeneity: Analysis of Treatment-Naïve Lesions. J Thorac Oncol 13:1496-1507

Showing the most recent 10 out of 435 publications